December 16, 2025 – Cambridge, Massachusetts — Atom Therapeutics has announced the initiation of a multi-regional Phase 2 clinical trial evaluating ABP-745, an investigational oral small-molecule therapy for atherosclerotic cardiovascular disease (ASCVD). The study marks a significant milestone in the company’s clinical development program, advancing a novel approach aimed at addressing residual inflammatory risk, a key driver of cardiovascular events that persists despite current standard-of-care therapies.
Science Significance
The Phase 2 trial of ABP-745 is scientifically notable because it targets inflammatory pathways implicated in atherosclerosis, rather than focusing solely on lipid reduction. ASCVD remains a leading cause of morbidity and mortality worldwide, even among patients optimally treated with statins and other lipid-lowering agents. ABP-745 is designed to modulate disease-driving inflammation, potentially reducing plaque instability and downstream cardiovascular events. The multi-regional design enhances the scientific robustness of the study by incorporating diverse patient populations, improving the generalizability of efficacy and safety data across different genetic and environmental backgrounds.
Regulatory Significance
From a regulatory standpoint, the launch of this Phase 2 study demonstrates continued compliance with global GxP and Good Clinical Practice (GCP) standards. Multi-regional trials require careful harmonization with regulatory authorities across jurisdictions, including alignment on protocol design, endpoint selection, and patient safety monitoring. Progression into Phase 2 also reflects regulatory confidence in the Phase 1 safety profile of ABP-745, positioning the program for future interactions related to end-of-Phase-2 guidance, dose selection, and potential accelerated development pathways if clinical benefit is demonstrated.
Business Significance
Advertisement
For Atom Therapeutics, advancing ABP-745 into Phase 2 strengthens its clinical-stage value proposition and elevates the company’s profile within the competitive cardiovascular drug development landscape. Cardiovascular disease represents one of the largest global pharmaceutical markets, yet innovation in anti-inflammatory mechanisms remains limited. Positive Phase 2 outcomes could significantly increase partnering, licensing, or investment interest, while validating Atom’s broader discovery platform. The multi-regional nature of the trial also signals commercial intent beyond a single geography, laying groundwork for future global development and commercialization strategies.
Patients’ Significance
For patients living with ASCVD, the trial represents renewed hope for therapies that go beyond cholesterol management. Many patients continue to experience heart attacks and strokes despite adherence to existing treatments, underscoring the unmet need for novel interventions. ABP-745 aims to address inflammation-driven risk, potentially offering improved cardiovascular protection and better long-term outcomes. Participation in this study also provides patients access to cutting-edge investigational therapy, while contributing to the advancement of knowledge that may benefit millions affected by cardiovascular disease worldwide.
Policy Significance
At a policy level, this clinical program aligns with global health priorities focused on reducing cardiovascular disease burden and healthcare costs. ASCVD-related hospitalizations and long-term care place substantial strain on healthcare systems. The development of therapies that reduce recurrent events could support value-based healthcare models and inform future treatment guidelines. Additionally, the multi-regional trial approach reflects policy trends encouraging inclusive, globally representative clinical research, ensuring that new therapies are evaluated across populations most affected by disease.
The initiation of Atom Therapeutics’ Phase 2 trial of ABP-745 marks a critical step in the evolution of inflammation-targeted cardiovascular therapeutics. By combining rigorous science, regulatory-aligned clinical development, and a patient-centered focus, the program underscores the growing importance of innovation in ASCVD treatment. As data from this study emerge, they will be closely watched by regulators, clinicians, and industry stakeholders seeking the next advancement in cardiovascular care.
Source: Atom Therapeutics press release
